328 related articles for article (PubMed ID: 18429824)
1. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
3. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
[TBL] [Abstract][Full Text] [Related]
4. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
5. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.
Rein MS; Friedman AJ; Pandian MR; Heffner LJ
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):388-94. PubMed ID: 2116610
[TBL] [Abstract][Full Text] [Related]
6. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
Saltiel E
Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
[TBL] [Abstract][Full Text] [Related]
7. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
[TBL] [Abstract][Full Text] [Related]
10. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
11. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
[TBL] [Abstract][Full Text] [Related]
12. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
Hansen LM; Batzer FR; Corson SL; Bello S
J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
[TBL] [Abstract][Full Text] [Related]
14. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern.
Di Lieto A; De Falco M; Mansueto G; De Rosa G; Pollio F; Staibano S
Steroids; 2005 Feb; 70(2):95-102. PubMed ID: 15631865
[TBL] [Abstract][Full Text] [Related]
15. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
16. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
[TBL] [Abstract][Full Text] [Related]
17. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
[TBL] [Abstract][Full Text] [Related]
18. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy before surgical treatment for uterine leiomyomas.
Moghissi KS
Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]